Characterization of familial chylomicronemia syndrome in a compound heterozygote for 2 APOA5 nonsense variants.

IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Paul A Mueller, Sara Rosario, Joshua Hay, Paige Bergstrom, Silvia Cecilia Pacheco-Velázquez, Robert A Hegele, Nathalie Pamir, Jonathan Q Purnell
{"title":"Characterization of familial chylomicronemia syndrome in a compound heterozygote for 2 APOA5 nonsense variants.","authors":"Paul A Mueller, Sara Rosario, Joshua Hay, Paige Bergstrom, Silvia Cecilia Pacheco-Velázquez, Robert A Hegele, Nathalie Pamir, Jonathan Q Purnell","doi":"10.1016/j.jacl.2025.04.196","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>A 3-year-old patient presented with severe hypertriglyceridemia and suspected familial chylomicronemia syndrome. Genetic analysis of the patient's DNA revealed the presence of 2 different heterozygous nonsense variants in the APOA5 gene encoding apolipoprotein (apo) A-V, namely p.Q275X and p.L242C fs X54. Our objective was to characterize the structural and functional consequences of the patient's co-occuring compound heterozygous variants in APOA5.</p><p><strong>Methods: </strong>Biozentrum's SWISS-MODEL was employed to predict the structure of apo A-V variants. Plasma from the patient and their family was used to determine lipid profiles, quantify apo C-II and apo C-III protein levels, and measure lipoprotein lipase (LPL) activity. High-density lipoprotein (HDL) was isolated from plasma and was used to assess sterol efflux capacity and proteome.</p><p><strong>Results: </strong>Structural characterization of the patient's APOA5 variants indicated premature truncation of the C-terminus of apo A-V that comprises the lipid binding domain. The patient's apo A-V was completely absent from the very-low density lipoprotein (VLDL) plasma fraction, associating almost exclusively with the low-density lipoprotein (LDL) and lipoprotein-free fractions. The patient's plasma also demonstrated reduced LPL activity and elevated apo C-II and C-III compared to other family members. The patient's HDL had the lowest sterol efflux capacity of all family members and a distinct proteome with reduced phospholipid transfer protein. Dietary intervention alone was effective in preventing recurring hypertriglyceridemia.</p><p><strong>Conclusions: </strong>These findings add to the current knowledge of apo A-V's role in plasma lipid homeostasis, pointing to a critical role for apo A-V binding to the lipoprotein particle in normal hydrolysis of triglyceride-rich lipoproteins.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jacl.2025.04.196","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: A 3-year-old patient presented with severe hypertriglyceridemia and suspected familial chylomicronemia syndrome. Genetic analysis of the patient's DNA revealed the presence of 2 different heterozygous nonsense variants in the APOA5 gene encoding apolipoprotein (apo) A-V, namely p.Q275X and p.L242C fs X54. Our objective was to characterize the structural and functional consequences of the patient's co-occuring compound heterozygous variants in APOA5.

Methods: Biozentrum's SWISS-MODEL was employed to predict the structure of apo A-V variants. Plasma from the patient and their family was used to determine lipid profiles, quantify apo C-II and apo C-III protein levels, and measure lipoprotein lipase (LPL) activity. High-density lipoprotein (HDL) was isolated from plasma and was used to assess sterol efflux capacity and proteome.

Results: Structural characterization of the patient's APOA5 variants indicated premature truncation of the C-terminus of apo A-V that comprises the lipid binding domain. The patient's apo A-V was completely absent from the very-low density lipoprotein (VLDL) plasma fraction, associating almost exclusively with the low-density lipoprotein (LDL) and lipoprotein-free fractions. The patient's plasma also demonstrated reduced LPL activity and elevated apo C-II and C-III compared to other family members. The patient's HDL had the lowest sterol efflux capacity of all family members and a distinct proteome with reduced phospholipid transfer protein. Dietary intervention alone was effective in preventing recurring hypertriglyceridemia.

Conclusions: These findings add to the current knowledge of apo A-V's role in plasma lipid homeostasis, pointing to a critical role for apo A-V binding to the lipoprotein particle in normal hydrolysis of triglyceride-rich lipoproteins.

2 APOA5无义变异体复合杂合子家族性乳糜微粒血症综合征的特征。
目的:1例3岁患儿表现为重度高甘油三酯血症并疑似家族性乳糜小血症综合征。对患者DNA的遗传分析显示,编码载脂蛋白(apo) A-V的APOA5基因存在2种不同的杂合无义变异,即p.Q275X和p.L242C fs X54。我们的目的是表征患者APOA5中共同发生的复合杂合变异的结构和功能后果。方法:采用Biozentrum的SWISS-MODEL预测载脂蛋白A-V变异的结构。患者及其家人的血浆用于测定血脂谱,定量载脂蛋白C-II和载脂蛋白C-III蛋白水平,并测量脂蛋白脂肪酶(LPL)活性。从血浆中分离高密度脂蛋白(HDL),用于评估甾醇外排能力和蛋白质组学。结果:患者APOA5变异的结构特征表明,包含脂质结合域的载脂蛋白A-V的c端过早截断。患者的载脂蛋白A-V在极低密度脂蛋白(VLDL)血浆组分中完全缺失,几乎完全与低密度脂蛋白(LDL)和无脂蛋白组分相关。与其他家庭成员相比,患者血浆中LPL活性降低,载脂蛋白C-II和C-III升高。患者的HDL具有所有家庭成员中最低的固醇外排能力,并且具有明显的蛋白质组,磷脂转移蛋白减少。单独的饮食干预对预防复发性高甘油三酯血症是有效的。结论:这些发现增加了载脂蛋白a - v在血浆脂质稳态中作用的现有知识,指出载脂蛋白a - v与脂蛋白颗粒结合在富含甘油三酯的脂蛋白的正常水解中起关键作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.00
自引率
6.80%
发文量
209
审稿时长
49 days
期刊介绍: Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. Sections of Journal of clinical lipidology will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信